Vir Biotechnology Inc
VIRHealthcare|Biotechnology|USA
$9.96
-0.38 (-3.68%)
Tangible Book
$4.89
Earnings Power
$9427.04
Upcoming Data Readouts (9)
Sep 2026
Est. completion
P1Hepatic Impairment
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
NCT05484206n=144
Nov 2026
Est. completion
P2Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
NCT07142811n=100
Dec 2026
Est. completion
P2For Treatment of Chronic Hepatitis B Virus Infection
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563n=150
Dec 2026
Est. completion
P3Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT07128550n=150
Dec 2026
Est. completion
P3Viral Hepatitis
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338n=124
Aug 2027
Est. completion
P1P2Locally Advanced or Metastatic HER2-Expressing Cancers
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
NCT05356741n=645
Sep 2027
Est. completion
P1Hormone-refractory Prostate Cancer
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
NCT05997615n=437
Aug 2029
Est. completion
P1Solid Tumor Malignancies
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06960395n=450
Nov 2031
Est. completion
P2Hepatitis D, Chronic
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
NCT05461170n=95
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2026
P1
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
NCT06070051Jul 2025
P2
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
NCT05970289